These tool and tech providers are investing the most in R&D among those in the biotechnology arena. [Natalia Merzlyakova - Fotolia.com]
#11. Danaher Life Sciences & Diagnostics4
2012 R&D spending: $418 million
2011 R&D spending: $341 million
% Change: 22.6%
2012 percentage of sales: 6.5%
2011 percentage of sales: 7.3%
#10. Bruker
2012 R&D spending: $195.3 million
2011 R&D spending: $177.2 million
% Change: 10.2%
2012 percentage of revenues: 10.9%
2011 percentage of revenues: 10.7%
#9. Merck Millipore5
2012 R&D spending: $212.890 million (€166.1 million)6
2011 R&D spending: $170.978 million (€133.4 million)6,7
% Change: 24.5%
2012 percentage of sales: 6.4%
2011 percentage of sales: 5.6%
#8. Bio-Rad Laboratories
2012 R&D spending: $214.040 million
2011 R&D spending: $186.439 million
% Change: 14.8%
2012 percentage of net sales: 10.3%
2011 percentage of net sales: 9.0%
#7. Illumina
2012 R&D spending: $231.025 million
2011 R&D spending: $196.913 million
% Change: 17.3%
2012 percentage of revenues: 20.1%
2011 percentage of revenues: 18.7%
#6. Thermo Fisher Scientific
2012 R&D spending: $376.4 million
2011 R&D spending: $340.2 million
% Change: 10.6%
2012 percentage of revenues: 3.0%
2011 percentage of revenues: 2.9%
#5. Life Technologies
2012 R&D spending: $341.892 million
2011 R&D spending: $377.924 million
% Change: -9.5%
2012 percentage of revenues: 9.0%
2011 percentage of revenues: 10.0%
#4. Becton Dickinson (BD)
2012 R&D spending: $471.755 million8
2011 R&D spending: $469.517 million8
% Change: 0.5%
2012 percentage of revenues: 6.1%
2011 percentage of revenues: 6.2%
#3. Agilent Technologies
2012 R&D spending: $668 million9
2011 R&D spending: $649 million9
% Change: 2.9%
2012 percentage of net revenues: 9.7%
2011 percentage of net revenues: 9.5%
#2. GE Healthcare10
2012 R&D spending: Approx. $1 billion11
2011 R&D spending: Approx. $1 billion11
% Change: No change
2012 percentage of revenues: about 5.5%
2011 percentage of revenues: about 5.5%
#1. Roche - Diagnostics Division12
2012 R&D spending: $1.078 billion (CHF 1.023 billion)13
2011 R&D spending: $978.914 million (CHF 929 million)13
% Change: 10.1%
2012 percentage of sales: 10.0%
2011 percentage of sales: 9.5%
Figures were disclosed by the companies in forms 10-K or 20-F, filed with the U.S. Securities and Exchange Commission (SEC); corporate annual reports; quarterly results press releases, and S-1 Securities Registration Statements also filed with the SEC. Where applicable, figures were converted to U.S. dollars from other currencies.
Notes:
1 R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.
2 Figure reported to one decimal place in March 25 press release announcing selected 2012 results.
3 R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.
4 Life Sciences & Diagnostics is the segment of Danaher Corp. that provides tools for biopharma research. Danaher’s life sciences business offer research and clinical tools used by scientists to study cells and cell components. Danaher’s diagnostics businesses offer analytical instruments, reagents, consumables, software and services used by hospitals, physician’s offices, reference laboratories and other critical care settings.
5 Merck Millipore is the division of Merck KGaA that supplies products and services for the life science industry. Key customer groups include research and analytical laboratories in the pharmaceutical/biotechnology industry or in academic institutions, and manufacturers of large and small molecule drugs.
6 R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.
7 Figure reduced from €134.5 million in 2011 annual report following shift of €1.1 billion for legal, financial and organizational functions to administration expenses.
8 BD’s fiscal years encompass the 12 months ending September 30.
9 Agilent’s fiscal years encompass the 12 months ending October 31.
10 Includes GE’s drug discovery and biopharmaceutical manufacturing technologies businesses, as well as businesses focused on medical imaging and information technologies, medical diagnostics, and patient monitoring systems.
11 Figures furnished by company to GEN. The figures vary from two previously published amounts. Last year, FierceMedicalDevices reported that the company’s 2011 R&D budget was $1.3 billion. However, a GE Healthcare presentation from the 4th University Forum in Brussels (March 22, 2011) stated that company R&D spending was “$1.5 billion,” though it was not stated if the figure covered 2011 or 2010.
12 Includes Roche’s Professional Diagnostics, Tissue Diagnostics, Diabetes Care, and Applied Science businesses.
13 R&D spending figures converted to USD via XE (www.xe.com) on March 29, 2013.